



Cambridge International AS & A Level

BIOLOGY

9700/22

Paper 2 AS Level Structured Questions

May/June 2021

MARK SCHEME

Maximum Mark: 60

Published

This mark scheme is published as an aid to teachers and candidates, to indicate the requirements of the examination. It shows the basis on which Examiners were instructed to award marks. It does not indicate the details of the discussions that took place at an Examiners' meeting before marking began, which would have considered the acceptability of alternative answers.

Mark schemes should be read in conjunction with the question paper and the Principal Examiner Report for Teachers.

Cambridge International will not enter into discussions about these mark schemes.

Cambridge International is publishing the mark schemes for the May/June 2021 series for most Cambridge IGCSE™, Cambridge International A and AS Level components and some Cambridge O Level components.

This document consists of **23** printed pages.

PUBLISHED**Generic Marking Principles**

These general marking principles must be applied by all examiners when marking candidate answers. They should be applied alongside the specific content of the mark scheme or generic level descriptors for a question. Each question paper and mark scheme will also comply with these marking principles.

GENERIC MARKING PRINCIPLE 1:

Marks must be awarded in line with:

- the specific content of the mark scheme or the generic level descriptors for the question
- the specific skills defined in the mark scheme or in the generic level descriptors for the question
- the standard of response required by a candidate as exemplified by the standardisation scripts.

GENERIC MARKING PRINCIPLE 2:

Marks awarded are always **whole marks** (not half marks, or other fractions).

GENERIC MARKING PRINCIPLE 3:

Marks must be awarded **positively**:

- marks are awarded for correct/valid answers, as defined in the mark scheme. However, credit is given for valid answers which go beyond the scope of the syllabus and mark scheme, referring to your Team Leader as appropriate
- marks are awarded when candidates clearly demonstrate what they know and can do
- marks are not deducted for errors
- marks are not deducted for omissions
- answers should only be judged on the quality of spelling, punctuation and grammar when these features are specifically assessed by the question as indicated by the mark scheme. The meaning, however, should be unambiguous.

GENERIC MARKING PRINCIPLE 4:

Rules must be applied consistently, e.g. in situations where candidates have not followed instructions or in the application of generic level descriptors.

GENERIC MARKING PRINCIPLE 5:

Marks should be awarded using the full range of marks defined in the mark scheme for the question (however; the use of the full mark range may be limited according to the quality of the candidate responses seen).

GENERIC MARKING PRINCIPLE 6:

Marks awarded are based solely on the requirements as defined in the mark scheme. Marks should not be awarded with grade thresholds or grade descriptors in mind.

Science-Specific Marking Principles

- 1 Examiners should consider the context and scientific use of any keywords when awarding marks. Although keywords may be present, marks should not be awarded if the keywords are used incorrectly.
- 2 The examiner should not choose between contradictory statements given in the same question part, and credit should not be awarded for any correct statement that is contradicted within the same question part. Wrong science that is irrelevant to the question should be ignored.
- 3 Although spellings do not have to be correct, spellings of syllabus terms must allow for clear and unambiguous separation from other syllabus terms with which they may be confused (e.g. ethane / ethene, glucagon / glycogen, refraction / reflection).
- 4 The error carried forward (ecf) principle should be applied, where appropriate. If an incorrect answer is subsequently used in a scientifically correct way, the candidate should be awarded these subsequent marking points. Further guidance will be included in the mark scheme where necessary and any exceptions to this general principle will be noted.
- 5 'List rule' guidance
 For questions that require *n* responses (e.g. State **two** reasons ...):
 - The response should be read as continuous prose, even when numbered answer spaces are provided.
 - Any response marked *ignore* in the mark scheme should not count towards *n*.
 - Incorrect responses should not be awarded credit but will still count towards *n*.
 - Read the entire response to check for any responses that contradict those that would otherwise be credited. Credit should **not** be awarded for any responses that are contradicted within the rest of the response. Where two responses contradict one another, this should be treated as a single incorrect response.
 - Non-contradictory responses after the first *n* responses may be ignored even if they include incorrect science.

6 Calculation specific guidance

Correct answers to calculations should be given full credit even if there is no working or incorrect working, **unless** the question states 'show your working'.

For questions in which the number of significant figures required is not stated, credit should be awarded for correct answers when rounded by the examiner to the number of significant figures given in the mark scheme. This may not apply to measured values.

For answers given in standard form (e.g. $a \times 10^n$) in which the convention of restricting the value of the coefficient (a) to a value between 1 and 10 is not followed, credit may still be awarded if the answer can be converted to the answer given in the mark scheme.

Unless a separate mark is given for a unit, a missing or incorrect unit will normally mean that the final calculation mark is not awarded. Exceptions to this general principle will be noted in the mark scheme.

7 Guidance for chemical equations

Multiples / fractions of coefficients used in chemical equations are acceptable unless stated otherwise in the mark scheme.

State symbols given in an equation should be ignored unless asked for in the question or stated otherwise in the mark scheme.

Examples of how to apply the list rule: State three reasons ... [3]

A	1. Correct	✓	2
	2. Correct	✓	
	3. Wrong	×	

C (4 responses)	1. Correct	✓	2
	2. Correct, Wrong	✓ ×	
	3. Correct	ignore	

E (4 responses)	1. Correct	✓	3
	2. Correct	✓	
	3. Correct, Wrong	✓	

G (5 responses)	1. Correct	✓	3
	2. Correct	✓	
	3. Correct Correct CON (of 4.)	✓ ignore ignore	

I (4 responses)	1. Correct	✓	2
	2. Correct	×	
	3. Correct CON (of 2.)	✓ (discount 2)	

B (4 responses)	1. Correct, Correct	✓ ✓	3
	2. Correct	✓	
	3. Wrong	ignore	

D (4 responses)	1. Correct	✓	2
	2. Correct, CON (of 2.)	×	
	3. Correct	✓	

F (4 responses)	1. Correct	✓	2
	2. Correct	✓	
	3. Correct CON (of 3.)	×	

H (4 responses)	1. Correct	✓	2
	2. Correct	×	
	3. CON (of 2.) Correct	(discount 2) ✓	

Mark scheme abbreviations:

;	separates marking points
/	alternative answers for the same marking point
R	reject
A	accept
I	ignore
AVP	any valid point
AW	alternative wording (where responses vary more than usual)
ecf	error carried forward
<u>underline</u>	actual word underlined must be used by candidate (grammatical variants accepted)
max	indicates the maximum number of marks that can be given
ora	or reverse argument
mp	marking point

Question	Answer	Marks
1(a)(i)	<p>E = metaphase ; F = anaphase ; I early / mid / late</p> <p>R more than one stage given for either E or F</p>	2
1(a)(ii)	<p><i>any one from</i> (assemble) to form / become part of / AW, spindle fibres / spindle ;</p> <p>attach to, centromere ; A kinetochore <i>for centromere</i> A form (part of) kinetochore A to connect, chromatid / chromosome, to, spindle / spindle fibres I to connect, chromosome / centromere, to centrosome</p> <p>example of allowing movement of, chromosomes / chromatids ; e.g. A to, pull chromosomes / orientate chromosomes, at equator A to pull (sister) chromatids apart (at anaphase) A to move, (sister) chromatids / daughter chromosomes, to poles</p>	1
1(a)(iii)	<p>must state 'plant' to gain mark I vacuoles / large permanent vacuole / vague ref. to shape</p> <p><i>any one from</i> cell walls present;</p> <p>uniform / regular, shape of cells ;</p> <p>no, cleavage furrow / pinching in of cytoplasm (in cells at cytokinesis) ;</p> <p>cell plate present (in late telophase / cytokinesis, stages) ;</p>	1

PUBLISHED

Question	Answer	Marks
1(b)	R <i>any answers where a choice is given</i> A hydrogen ; B (DNA) ligase ; C <u>DNA</u> polymerase ; R RNA polymerase I roman numerals, e.g. DNA polymerase I D telomeres ;	4

PUBLISHED

Question	Answer	Marks
2(a)	<p><i>any three from decrease in sugar</i></p> <p>1 <i>idea that</i> changing / transition, from sink to source e.g. leaf becomes the source leaf no longer the sink sugars are (now) being moved away from leaf was a growing area, now translocating (sugars)</p> <p>2 photosynthesis provides enough sugar / (rate of) photosynthesis increases ; A leaf (now) makes enough sugar I makes own food</p> <p><i>increase in water to max 2</i></p> <p>3 increase in size / more cells / increase in (leaf) surface area, (so proportionate increase in water) ;</p> <p>4 (more cells that need) water to, maintain turgidity / prevent flaccidity / prevent wilting, (because of transpiration) ;</p> <p>5 increased transpiration / greater number of stomata ; A increased evaporation (greater internal leaf area)</p> <p>6 water is, a reactant / needed, for photosynthesis ; <i>(in context of increased photosynthesis, more water needed)</i></p> <p>7 AVP ; e.g. maturing leaf growth rate slows / mature leaf no growth (more cells, so more) water needed for, cellular reactions / AW e.g. for hydrolysis of starch (more) water needed for, cell elongation / enlarging vacuoles</p>	3

Question	Answer				Marks																				
2(b)	<p><i>one mark each correct row ;;;</i></p> <p><i>column mark can be used <u>instead of</u> row mark (if higher mark achieved)</i></p> <table border="1" data-bbox="331 352 1341 746"> <thead> <tr> <th data-bbox="331 352 584 448">feature</th> <th data-bbox="584 352 837 448">companion cells</th> <th data-bbox="837 352 1090 448">phloem sieve tube element</th> <th data-bbox="1090 352 1341 448">xylem vessel element</th> </tr> </thead> <tbody> <tr> <td data-bbox="331 448 584 517">cytoplasm</td> <td data-bbox="584 448 837 517">✓</td> <td data-bbox="837 448 1090 517">✓</td> <td data-bbox="1090 448 1341 517">x</td> </tr> <tr> <td data-bbox="331 517 584 612">cell surface membrane</td> <td data-bbox="584 517 837 612">✓</td> <td data-bbox="837 517 1090 612">✓</td> <td data-bbox="1090 517 1341 612">x</td> </tr> <tr> <td data-bbox="331 612 584 681">lignified cell wall</td> <td data-bbox="584 612 837 681">x</td> <td data-bbox="837 612 1090 681">x</td> <td data-bbox="1090 612 1341 681">✓</td> </tr> <tr> <td data-bbox="331 681 584 746">nucleus</td> <td data-bbox="584 681 837 746">✓</td> <td data-bbox="837 681 1090 746">x</td> <td data-bbox="1090 681 1341 746">x</td> </tr> </tbody> </table>				feature	companion cells	phloem sieve tube element	xylem vessel element	cytoplasm	✓	✓	x	cell surface membrane	✓	✓	x	lignified cell wall	x	x	✓	nucleus	✓	x	x	4
feature	companion cells	phloem sieve tube element	xylem vessel element																						
cytoplasm	✓	✓	x																						
cell surface membrane	✓	✓	x																						
lignified cell wall	x	x	✓																						
nucleus	✓	x	x																						

PUBLISHED

Question	Answer			Marks
3(a)(i)	<i>accept from either column for mark and assume blood if not stated any three from</i>			3
blood	tissue fluid			
has red blood cells	has no red blood cells	;		
more, white blood cells / leucocytes / named e.g. neutrophils, lymphocytes, monocytes or fewer macrophages	fewer white blood cells / leucocytes / named e.g. neutrophils, lymphocytes, monocytes or more macrophages	;		
has platelets	has no platelets	;		
has, more protein / large proteins or has, plasma proteins / named example e.g albumin / fibrinogen / globulin <i>these are large proteins</i>	has, fewer / no large, proteins or has no, plasma proteins / named example e.g. albumin / fibrinogen / globulin <i>only allow fewer plasma proteins if clear the proteins present are small enough to leave blood</i>	;		
higher, concentration / AW, oxygen A more oxygenated	lower, concentration / AW, oxygen A less oxygenated	;		
higher, concentration / AW, glucose / amino acids / fatty acids	lower, concentration / AW, glucose / amino acids / fatty acids	;		
lower, concentration / AW, carbon dioxide in liver / muscles I waste	higher, concentration / AW, carbon dioxide urea, in liver / muscles I waste	;		
higher pressure	lower pressure	;		
3(a)(ii)	lymph ; A lymphatic fluid			1

PUBLISHED

Question	Answer	Marks
3(b)	<p><i>any two from:</i></p> <p>1 can cross / AW, hydrophobic core (of bilayer) / phospholipid bilayer or can pass through gaps between, fatty acid tails / phospholipids ;</p> <p>2 is, hydrophobic / lipid-soluble / non-polar / not ionic / not charged or not, hydrophilic / water-soluble / polar / ionic / charged ;</p> <p>3 small size ;</p>	2
3(c)	<p>Reject if hormone S or receptor R described as an antigen or enzyme</p> <p>complementary (shape) to / only fits into / specificity for (binding to), R / receptor ;</p>	1
3(d)(i)	nuclear pore ; A nuclear pores	1
3(d)(ii)	<p>B = transcription ;</p> <p>C = translation ;</p>	2
3(d)(iii)	(80S) ribosome ; I 70S	1

PUBLISHED

Question	Answer	Marks
3(e)	<p><i>any four from</i></p> <p>1 (formation of), secondary / 2° / second level, structure with, alpha-helix / α-helix / beta-pleated sheet(s) / β-pleated sheet(s) ; A β-conformation for β-pleated sheet I incorrect detail of bonds</p> <p>2 folding / coiling, to form tertiary / 3° / third level, structure ; A ref. to 3D structure as alternative to, folding / coiling A secondary structure, folds / coils, to form tertiary structure R alpha helix / beta-pleated sheet, coils / folds</p> <p>3 <i>two of</i> hydrogen bonds / ionic or electrostatic bonds / disulfide bonds or bridges / hydrophobic interactions ; I peptide bonds <i>as part of a list that contains two correct bond types</i> <i>these must be in context of tertiary structure</i></p> <p>4 (formation of), quaternary / 4° / fourth level structure ; A description e.g. polypeptides held together by, interactions / hydrogen bonds / ionic bonds / disulfide bonds R if peptide bonds included</p> <p>5 (globular protein) has hydrophilic, amino acids / R-groups / side chains, to, outside / AW ; ora hydrophobic, amino acids / R-groups / side chains, towards centre / AW</p> <p>6 example of other post-translational modification ; e.g. removal, methionine / met addition sugar group / glycosylation addition phosphate group / phosphorylation addition prosthetic group</p>	4

PUBLISHED

Question	Answer	Marks
4(a)	<p><i>any three from lung cancer to max 2</i> (tar) is a carcinogen ; acts as mutagen / causes mutations / described ; I mutant cells e.g. causes changes to sequence of, bases / nucleotides, in DNA</p> <p>detail ; I uncontrolled mitosis e.g. tumour suppressor genes switched off protooncogenes to oncogenes / oncogenes switched on (cell cycle) checkpoints fail to function AW cell moves from, G0 / inactive state of cell cycle, to G1 phase (for mitosis) no programmed death / AW</p> <p><i>chronic bronchitis to max 2</i> (tar) paralyses / destroys / damages / AW, cilia ; I weakens cilia A damage to <u>ciliated</u> (epithelial) cells consequence to <u>cilia</u> action ; <i>must be related to mp1</i> e.g. <u>cilia</u> do not, waft away / AW, mucus loss of synchronous rhythm of <u>cilia</u></p> <p>(tar causes), goblet cells / mucous glands, to, increase in size / enlarge / AW ; A (tar / accumulation of mucus, causes) inflammation</p> <p>more / excess, mucus produced (by, goblet / mucous gland cells) ; I mucus accumulates</p>	3
4(b)	<p><i>correct units for volume cm³ ;</i></p> <p><i>SA <u>and</u> volume calculation (SA) = 54 (V) = 27 ;</i></p>	2
4(c)	A → B → C ; A 6:1 → 3:1 → 2:1 A 1 → 2 → 3	1

PUBLISHED

Question	Answer	Marks
4(d)	<p><i>any two from (in emphysema)</i> alveolar walls break down / alveoli burst, to, produce one large air sac / give a lower SA:V or diseased, tissue / areas / alveoli, has lower SA:V (than healthy tissue) ;</p> <p>removed tissue has (higher proportion of), large air sacs / diseased alveoli ;</p> <p>remaining tissue has, healthy / undamaged / functional / only, alveoli ; AW A volume reduced and functional surface area of lung remains the same A remaining tissue has higher functional surface area (than before surgery)</p>	2
4(e)	<p><i>any two from</i></p> <p>1 <u>only</u> oxygenated blood passes through left side of heart ora or oxygenated blood in left side and deoxygenated blood in right side of heart ;</p> <p>2 septum in heart separates (oxygenated and deoxygenated) blood ;</p> <p>3 oxygenated blood is in pulmonary, venules / veins <u>and</u> deoxygenated blood is in, pulmonary arteries / arterioles ;</p> <p>4 (because mixing prevented by) double circulation / double circulatory system / pulmonary and systemic circulations ;</p>	2
5(a)	<p>plasmodesma ;</p> <p><i>plus any one from</i> R if stated as apoplast</p> <p>1 allows / AW, <u>symplast</u>, pathway / movement ;</p> <p>2 allows transport of / AW, water / sucrose / sugars / amino acids / organic substances / ions / mineral salts (A minerals) / lipids / assimilates / hormones / cell signalling molecules ; <i>in context of</i> between cells I substance unqualified I osmosis of water if in a longer list where other substances are named correctly R osmosis of water <i>if this is the only item noted</i></p> <p>3 cell to cell / AW, communication / signalling ; A cell communication</p>	2

PUBLISHED

Question	Answer	Marks
5(b)(i)	<i>any one from</i> (only) polypeptides / proteins, synthesised at ribosomes ; carbohydrates / polysaccharides, not synthesised at ribosomes ; enzymes, for synthesis / required, not located at ribosomes ;	1
5(b)(ii)	exocytosis ;	1

PUBLISHED

Question	Answer	Marks
5(c)	<p><i>accept substrate for cellulose and enzyme for cellulase</i></p> <p><i>allow use of extracted data to support a response to confirm awarding a mark</i></p> <p>1 correct description ; <i>overall trend or more detailed break down</i></p> <p>e.g. as, cellulose / substrate, concentration increases, rate of reaction increases or as, cellulose / substrate, concentration increases, steep increase in rate of reaction then, less steep increase / (begins to) plateau</p> <p>I 'rate of reaction is fast and then slows down' <i>needs ref. to rate of reaction, describing 'gradient of curve' is not enough</i></p> <p><i>plus any two from</i></p> <p>2 increasing cellulose concentration increases number of, collisions between enzyme and substrate / enzyme-substrate complexes / ESCs ; A collisions between active site and substrate A <i>idea of</i> increased chances of cellulose binding to active site</p> <p>3 at low cellulose concentrations, (many) active sites, available / not all used / not saturated ;</p> <p>4 at higher cellulose concentrations, active sites becoming saturated / most active sites occupied / most active sites not available / AW ; A active sites are, saturated / occupied</p> <p>5 named limiting factor(s), qualified ; e.g. at low(er) cellulose concentrations, cellulose concentration limiting / enzyme concentration not limiting A idea of, not enough cellulose / enzyme in excess as cellulose concentration increases, change from cellulose concentration limiting to enzyme concentration as limiting factor at higher cellulose concentrations, enzyme concentration limiting / cellulose concentration not limiting A idea of, cellulose in excess / not enough enzyme / enzyme working at its fastest rate / active sites not emptying quickly enough for substrate available</p>	3

PUBLISHED

Question	Answer	Marks
5(d)(i)	<p><i>mark to max 2 if microorganisms are considered to be enzyme inhibitors</i></p> <p><i>lower K_m for pectinase, any two from ultrasound</i> increases affinity of enzyme for substrate ;</p> <p>makes shape of active site more complementary ;</p> <p>makes (position of) active site more accessible (to substrate) ; A makes it easier for substrate to enter (active site)</p> <p>breaks up pectin, aggregates / AW, to expose more substrate for binding ;</p> <p><i>higher V_{max} for xylanase, any two from ultrasound</i> increases rate of, collision between enzyme and substrate / more enzyme-substrate complexes per unit time ; I more ESC form <i>needs idea of increased rate</i></p> <p>increases rate of catalysis after binding ;</p> <p>may change substrate for easier hydrolysis ;</p> <p>may lower, more than normal, activation energy required for reaction ; A described, e.g. increased ability to, break / form, bonds</p>	3
5(d)(ii)	<p>yes (as all have) increased, catalytic efficiency / productivity / V_{max}/K_m ; A manipulated data for increased catalytic efficiency <i>any <u>two</u> from</i> pectin 24.5 / 25% cellulase 17.25 / 17% xylanase 16.8 / 17%</p>	1

PUBLISHED

Question	Answer	Marks
6(a)	<p><i>any two from</i></p> <p>1 (MG is an) autoimmune, disease / disorder / condition ; A autoimmunity R autoimmune system</p> <p>2 (disease in which) failure to distinguish / AW, between self and, non-self ; A between self and, non-self / foreign, antigens</p> <p>3 (so, at neuromuscular junctions) ref. immune response occurs against / antibody produced against, self- <u>antigens</u> / receptors qualified (see list); A antibodies, bind to / block / attack / AW</p> <p>examples of receptors cell surface muscle cell ACh / neurotransmitter neuromuscular junction postsynaptic</p> <p>4 <i>idea that</i> defective lymphocytes not destroyed (during development) ;</p>	2

PUBLISHED

Question	Answer	Marks
6(b)	<p><i>max 2 if wrong context</i> <i>e.g. vaccine contains, foreign antigens / antigens of pathogen / pathogen / antibody to bind to lymphocytes</i></p> <p><i>any three from</i></p> <p>1 vaccine contains antigens ; <i>in context of antigens of defective, T-lymphocytes and B-lymphocytes</i> <i>(accept antibody of defective B-lymphocyte as AW antigen)</i></p> <p>2 stimulates an immune response ;</p> <p>3 detail ; e.g. macrophages and antigen presentation / AW <i>ref. to specific lymphocytes involved</i> <i>clonal selection of lymphocytes</i> <i>recognition by / activation of, lymphocytes</i> <i>clonal expansion of lymphocytes</i> <i>production of plasma cells in context of B-lymphocytes</i> <i>production of memory cells</i> <i>T-helper cells produce cytokine</i></p> <p>4 antibody produced against (defective), T-lymphocytes / B-lymphocytes / antibody (that binds ACh receptors) ; <i>in context of primary or secondary response</i> R <i>if context is related to the vaccine containing antibody</i></p> <p>5 memory cells, remain / give long-lasting effect / AW ;</p> <p>6 memory cells allow secondary immune response to (defective) lymphocytes (newly produced) ;</p>	3

PUBLISHED

Question	Answer	Marks
6(c)	<p><i>any one from</i> antibiotic resistance, qualified ; A drug for antibiotic e.g. increases risk of antibiotic resistance developing may cause / could lead to problems of, antibiotic resistance an antibiotic resistant bacterial strain may develop</p> <p>R if, immune / immunity, included R antibiotic resistance / mutation, in, TB / disease / people / virus</p> <p>mutation(s) occur in <u>bacteria</u> which, make antibiotics ineffective / prevent antibiotic action ; A mutation occurs which may make bacteria resistant</p> <p>AVP ; e.g. <i>ref. to</i> development of, DR-TB / MDR-TB / XDR-TB <i>(if latent bacteria become active)</i></p>	1

PUBLISHED

Question	Answer	Marks
6(d)	<p><i>max 2 if not in context of the statistic stated (using only Fig. 6.1) mps 2 -8 only</i></p> <p><i>points are in context of people who do not know</i></p> <p><i>any three from</i></p> <p>1 9.2 million do not know that they are, living / infected with, HIV ; ora 27.7 million people know</p> <p><i>risk to themselves</i></p> <p>2 not accessing, ART / treatment ; A only people who know will access ART A if tested, can access ART</p> <p>3 high(er) viral, loads / levels (compared to many on ART); ora <i>idea of no control over presence of virus in body</i></p> <p>4 greater risk of, developing / dying from, <u>HIV/AIDS</u> / HIV-related diseases ; ora A AIDS for HIV / AIDS R HIV <i>context could be, no ART / higher viral loads / no treatment of HIV-related diseases</i> <i>risk to others</i></p> <p>5 greater risk of transmitting, virus / HIV ; ora <i>includes placental transmission</i></p> <p>R HIV/AIDS or AIDS <i>context could be, higher viral load / not practising prevention</i></p> <p>6 detail of prevention that may not be practised ; ora e.g. are sharing contaminated needles are donating blood are breastfeeding are not, practising safe sex / using condoms / AW</p> <p>7 (may develop opportunistic infection so) greater risk of spreading infectious diseases ; <i>consequence for, health care / authorities</i></p>	3

PUBLISHED

Question	Answer	Marks
6(d)	<p>8 problems with increase in infection within a population ; ora e.g. increased cost of, care / medication increased pressure on medical staff reduction in size of labour force</p> <p>9 <i>ref. to</i> testing for HIV ; R testing for HIV/AIDS e.g. indicates more, education / advertising, needed to encourage testing indicates more testing required / focusing on at risk groups</p> <p>10 AVP ; <i>issues for authorities other than mp 8 and 9</i> e.g. if people do not know status, no contact tracing can occur focus efforts on countries where a high proportion do not know HIV status authorities provide free condoms to try and reduce overall transmission</p>	